Galapagos has achieved two milestones totaling $3.5 million in its strategic alliances with Janssen Pharmaceutica and GlaxoSmithKline. Galapagos received a $2.1 million milestone payment from Janssen related to their rheumatoid arthritis (RA) alliance, under which Galapagos has earned more than $33.4 million in payments so far. Under this alliance Galapagos provides Janssen with option rights to acquire worldwide, commercial licenses to novel small molecules from its internal programs involv...